Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Renal Cell 64Neoplasm Metastasis 25Kidney Neoplasms 21Neoplasms 16Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 12Prostatic Neoplasms 10Lung Neoplasms 8Brain Neoplasms 8Melanoma 7Colorectal Neoplasms 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Neuroendocrine Tumors 6Liver Neoplasms 6Glioblastoma 6Gastrointestinal Stromal Tumors 6Carcinoma, Hepatocellular 6Thyroid Neoplasms 5Thymoma 5Small Cell Lung Carcinoma 5Recurrence 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma 5Uveal Melanoma 4Stomach Neoplasms 4Sarcoma 4Adenocarcinoma 4

Interventions

Paclitaxel 56Carboplatin 56Bevacizumab 43Gemcitabine 20Taxes 19pembrolizumab 15Immunoglobulin G 13Disulfides 13Topotecan 12olaparib 11Cisplatin 11niraparib 9Cyclophosphamide 9liposomal doxorubicin 8Specimen Handling 7Docetaxel 6Biopsy 6mirvetuximab soravtansine 5Nivolumab 5Magnetic Resonance Spectroscopy 5Letrozole 5Hyperthermic Intraperitoneal Chemotherapy 5Drug Therapy 5Cytoreduction Surgical Procedures 5Albumin-Bound Paclitaxel 5rucaparib 4pazopanib 4oregovomab 4Surgical Procedures, Operative 4Neoadjuvant Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Neoplasms × Sunitinib × Clear all
NCT00768144 2018-08-24

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Dana-Farber Cancer Institute

Phase 2 Completed
36 enrolled 10 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00388037 2015-01-27

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00543049 2014-03-07

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

AGO Study Group

Phase 2 Completed
73 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡